Case Report: Upadacitinib for SAPHO syndrome with biologics-induced paradoxical manifestation and Hyperimmunoglobulinemia E
This case suggests that upadacitinib may be a valuable therapeutic option for patients with refractory SAPHO syndrome, particularly those presenting with paradoxical reactions or hypersensitivity. The unique mechanism of action of Janus kinase (JAK) inhibitors may offer superior efficacy in such cases, though further clinical validation and mechanistic studies are warranted.
Authors
- Wen Shen Dong Li
- Yuxi Liu (ORCID: https://orcid.org/0000-0003-1265-7926)
- Chen Li
- Di Jin (ORCID: https://orcid.org/0009-0001-4646-5220)
- Xin Li
- Shiqi Zhang
Institutions
- Tianjin University of Traditional Chinese Medicine (CN)
- Beijing University of Chinese Medicine (CN)
- Tianjin Medical University General Hospital (CN)
- Weifang People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3389/fimmu.2026.1728245
- Citations
- 1
- Primary Topic
- Osteomyelitis and Bone Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 46.80
Funders
- National Natural Science Foundation of China